Valuation: Allergy Therapeutics plc

Market Cap 418M 559M 489M 451M 793M 53.06B 806M 5.41B 2.1B 26.19B 2.1B 2.05B 90.52B P/E 2026 *
-8.53x
P/E 2027 * -
Enterprise Value 456M 610M 534M 492M 865M 57.86B 879M 5.9B 2.29B 28.56B 2.29B 2.24B 98.71B EV / Sales 2026 *
7.23x
EV / Sales 2027 * -
Free-Float
11.51%
Yield 2026 *
-
Yield 2027 * -
1 day-3.23%
1 week-7.04%
Current month-7.04%
1 month-25.51%
3 months-38.89%
6 months-44.54%
Current year-40.00%
1 week 6
Extreme 6
7.56
1 month 6
Extreme 6
9
Current year 6
Extreme 6
12.1
1 year 6
Extreme 6
12.1
3 years 1.2
Extreme 1.2
12.1
5 years 0.8
Extreme 0.8
40.5
10 years 0.8
Extreme 0.8
40.5
Manager TitleAgeSince
Chief Executive Officer 62 2009-08-31
Director of Finance/CFO - 2023-08-10
Corporate Officer/Principal 62 2026-01-28
Director TitleAgeSince
Director/Board Member 62 2009-08-31
Chairman 75 2011-01-03
Director/Board Member 69 2017-06-05
Date Insider Type Main position Quantity % Market Cap.
06-12Free

Chief Financial Officer

2,300,000 0.0363%
03-11
ZQ Capital Ltd.
SellCompany 14,742,000 0.2400%
03-11
ZQ Capital Ltd.
OthersCompany 150,925,926 2.4575%
Change 5-day change 1-year change 3-year change Capi.($)
-3.23%-7.04%-17.50%+355.17% 577M
+4.07%+8.45%+25.67%-2.34% 66.11B
-0.24%-3.68%+50.27%+220.37% 55.3B
+1.21%+42.20%+42.20%+42.20% 42.44B
-0.21%+7.44%-48.93%-54.50% 41.28B
-2.48%+13.91%+166.79%-32.89% 32.46B
-1.32%-4.79%+58.07%-25.22% 30.78B
+2.10%+4.14%+75.49%+90.19% 23.1B
-3.65%+8.93%+1.16%+184.50% 20.06B
-0.04%+3.85%+67.76%+135.89% 17.19B
Average -0.42%+4.54%+42.10%+91.34% 32.93B
Weighted average by Cap. +0.41%+4.15%+43.64%+54.82%

Financials

2026 *2027 *
Net sales 63M 84.28M 73.75M 67.97M 120M 8B 122M 815M 317M 3.95B 316M 310M 13.64B -
Net income -49.3M -65.95M -57.71M -53.19M -93.59M -6.26B -95.1M -638M -248M -3.09B -248M -242M -10.68B -
Net Debt 37.8M 50.57M 44.25M 40.78M 71.76M 4.8B 72.91M 489M 190M 2.37B 190M 186M 8.19B -
Logo Allergy Therapeutics plc
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Employees
584
Date Price Change Volume
26-07-07 GBX 6.600 -3.23% 152,417
26-07-06 GBX 6.820 +3.33% 116,963
26-07-03 GBX 6.600 +2.17% 233,084
26-07-02 GBX 6.460 +2.54% 590,892
26-07-01 GBX 6.300 -11.27% 225,350
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0660GBP
Average target price
0.1300GBP
Spread / Average Target
+96.97%

Annual profits - Rate of surprise